Quantitative Investment Management LLC purchased a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 13,800 shares of the biotechnology company’s stock, valued at approximately $1,253,000.

Other institutional investors have also modified their holdings of the company. Swiss National Bank lifted its holdings in BioMarin Pharmaceutical by 3.6% during the second quarter. Swiss National Bank now owns 631,600 shares of the biotechnology company’s stock worth $57,362,000 after acquiring an additional 22,200 shares during the period. Aperio Group LLC lifted its holdings in BioMarin Pharmaceutical by 9.7% during the second quarter. Aperio Group LLC now owns 56,491 shares of the biotechnology company’s stock worth $5,131,000 after acquiring an additional 5,006 shares during the period. UBS Asset Management Americas Inc. lifted its holdings in BioMarin Pharmaceutical by 11.3% during the first quarter. UBS Asset Management Americas Inc. now owns 1,087,995 shares of the biotechnology company’s stock worth $95,504,000 after acquiring an additional 110,504 shares during the period. Prudential Financial Inc. lifted its holdings in BioMarin Pharmaceutical by 2.9% during the second quarter. Prudential Financial Inc. now owns 145,170 shares of the biotechnology company’s stock worth $13,185,000 after acquiring an additional 4,026 shares during the period. Finally, Eagle Asset Management Inc. lifted its holdings in BioMarin Pharmaceutical by 21.7% during the second quarter. Eagle Asset Management Inc. now owns 306,353 shares of the biotechnology company’s stock worth $27,822,000 after acquiring an additional 54,675 shares during the period. Institutional investors and hedge funds own 97.46% of the company’s stock.

BMRN has been the topic of a number of recent analyst reports. Sanford C. Bernstein initiated coverage on BioMarin Pharmaceutical in a report on Thursday, July 27th. They set a “market perform” rating and a $89.00 price target on the stock. Evercore ISI initiated coverage on BioMarin Pharmaceutical in a report on Wednesday, August 16th. They set an “outperform” rating and a $100.00 price target on the stock. Royal Bank Of Canada initiated coverage on BioMarin Pharmaceutical in a report on Thursday, September 14th. They set a “sector perform” rating and a $93.00 price target on the stock. SunTrust Banks, Inc. reiterated a “buy” rating and set a $115.00 price target on shares of BioMarin Pharmaceutical in a report on Friday, July 14th. Finally, Barclays PLC reiterated an “equal weight” rating and set a $100.00 price target (down from $105.00) on shares of BioMarin Pharmaceutical in a report on Saturday, July 22nd. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and fifteen have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $109.09.

In other BioMarin Pharmaceutical news, EVP Jeffrey Robert Ajer sold 3,521 shares of the stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $95.00, for a total value of $334,495.00. Following the completion of the sale, the executive vice president now owns 49,299 shares in the company, valued at approximately $4,683,405. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Henry J. Fuchs sold 15,000 shares of the stock in a transaction on Friday, September 15th. The stock was sold at an average price of $90.50, for a total value of $1,357,500.00. Following the completion of the sale, the insider now owns 141,422 shares of the company’s stock, valued at approximately $12,798,691. The disclosure for this sale can be found here. Insiders sold a total of 22,271 shares of company stock valued at $2,034,220 in the last quarter. 2.50% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “Quantitative Investment Management LLC Purchases Shares of 13,800 BioMarin Pharmaceutical Inc. (BMRN)” was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.watchlistnews.com/quantitative-investment-management-llc-purchases-shares-of-13800-biomarin-pharmaceutical-inc-bmrn/1600491.html.

BioMarin Pharmaceutical Inc. (NASDAQ BMRN) opened at 93.07 on Friday. The stock’s market capitalization is $16.31 billion. The company’s 50-day moving average price is $86.72 and its 200 day moving average price is $89.48. BioMarin Pharmaceutical Inc. has a 52-week low of $78.42 and a 52-week high of $100.51.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.01. BioMarin Pharmaceutical had a negative return on equity of 5.77% and a negative net margin of 15.54%. The business had revenue of $317.50 million during the quarter, compared to analyst estimates of $311.41 million. During the same quarter in the prior year, the business posted ($2.61) EPS. BioMarin Pharmaceutical’s revenue for the quarter was up 5.8% compared to the same quarter last year. Equities analysts forecast that BioMarin Pharmaceutical Inc. will post ($0.71) EPS for the current fiscal year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.